The neuroscience of sleep: Russell Foster at TEDGlobal 2013

First Friday Book Synopsis

Bob''s blog entries Biotechnology and Biological Sciences Research Council Brasenose College at the University of Oxford James Duncan Davidson Margaret Thatcher: “Sleep is for wimps” Royal Society Sleep is for energy conservation [comma] to save calories Sleep is for restoration [comma] to replenish and repair metabolic processes Sleep: A Very Short Introduction Steven W. Here is an excerpt from an article posted by Thu-Huong Ha at the TED website.

Executive Presence Training

Career Advancement

For example, a multi-billion-dollar biotechnology company recently contacted me for a training on executive presence to help newly minted high-potential mid-level managers reach the next level of leadership.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Top 25 Companies for Pay and Perks (USA Today)

Chart Your Course

Pharmaceutical and biotechnology make up the second-largest group with three representatives: Genentech, Amgen and Pfizer. The top 25 companies for pay and perks. Casey Kelly-Barton, The Motley Fool. Source: USA Today.

Which Business Sectors Are Attracting Investment?

Strategy Driven

There have also been great leaps forward in biotechnology and even people without investment experience in the industry can find a niche sector to become involved in.

Managing Distraction in the Digital Era

Great Leadership By Dan

Guest post from Amy Blankson: In 2013, the National Center for Biotechnology Information reported that the average attention span of a human has dropped to a mere eight seconds , one second behind that of a goldfish.

A Lesson On Bringing Out The Best In Those You Lead

Tanveer Naseer

Dan was the president of a biotechnology company where I served in my first middle management role. Over the past few weeks, I’ve been writing about the various characteristics and perspectives leaders need to have to be successful in bringing out the best in those they lead.

Understanding The Power Of Our Words

Tanveer Naseer

The first leader was someone I worked with as part of the management team at a biotechnology firm, and how he guided our organization during the merger of our North American parent company with a much larger European multinational.

Power 268

Meet The Earnest Newcomer. Was This You?

The Idolbuster

While Silicon Valley is best known for their technology companies – Google, Yahoo, Apple, Hewlett Packard, Intel, and Facebook to name a few, the Bay Area is also home to some of the most cutting edge biotechnology and medical device companies. The job at a small biotechnology company was a great match for his skills. Chapter 4: Who To Trust At Work Post 2.

How to Compete Like the World’s Most Innovative Leaders

Skip Prichard

Unfortunately, many of us have developed expertise in only one field (software engineering, information technology [IT], marketing, biotechnology, automobile manufacturing, the food industry, etc. Innovation Capital. A great idea may not be enough to build a great business.

How To Have Sustainable Success

The Idolbuster

Prior to launching her wellness practice, she worked in the management consulting industry and at one of the leading cancer research biotechnology companies. Self Portrait By Jillian Corinne Via Flickr CC. A guest post by Health Coach Catherine Chen, Ph.D. Do you sometimes fall into this trap?

Best Paid Jobs of 2019 | Glassdoor

HR Digest

There are some other categories not listed here which are showing remarkable growth, including life sciences and biotechnology and research. Healthcare professionals are outperforming the computer geeks of the world in salary stakes, according to some surveys.

Why You Should Care About The Revenue Forecast

The Idolbuster

I heard a cautionary tale from “George” the former VP of marketing at a mid-sized biotechnology company about how a bogus forecast helped propagate a disaster. Chapter 9: Paint Your Environment: Part 5. As I argued in the last post , if you want the company to do the right thing, make sure you have a set of numbers to back it up. To fully understand why I think this is critical, lets step back for a moment and look at where a revenue forecast come from.

A Simple Workaround to Overcome the Bureaucratic Mindset

Tanveer Naseer

Russell is an educational psychologist, author, executive coach and management consultant whose clients include Fortune 500 executives in aerospace, healthcare, pharmaceutical and biotechnology, information technology, telecommunications and oil and gas. The following is a guest post by Russell Bishop.

Which Messages Go Viral and Which Ones Don’t

Harvard Business Review

For example, if you are a biotechnology fund manager who wants to communicate the importance of investing in biotechnology, you may think that your value is in your recent success in investing for shareholders, but if you are a reasonable person, you will likely also have doubts about this. How will they feel about the fact that you have a history of success in biotechnology investing?

A Quiet Revolution in Clean-Energy Finance

Harvard Business Review

Their behavior displays promising parallels to the early days of the biotechnology industry. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive. Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies.

IPO 17

Information Technology's Dangerous Trend in Africa

Harvard Business Review

For the past few decades, emerging technologies such as biotechnology, microelectronics, information technology and communications technologies have become central to the socioeconomic development of nations. These technologies improve productivity and facilitate better living standards when they penetrate into societies.

50 Laboratories of Opportunity

Harvard Business Review

Is it possible that local funding could help bolster tourism in Florida, biotechnology in California, publishing in New York, and agriculture in Iowa? One thing that the Chinese do quite well — and that the U.S. could learn from — is to test policy proposals before rolling them out nationally. A new approach is often tried out first in several cities or provinces to make sure it has the intended effect, and to check for unintended consequences.

Research: The Average Age of a Successful Startup Founder Is 45

Harvard Business Review

However, young people are less common in other industries such as oil and gas or biotechnology, where the average age is closer to 47. Patricia de Melo Moreira/bloomberg/Getty Images. It’s widely believed that the most successful entrepreneurs are young. Bill Gates, Steve Jobs, and Mark Zuckerberg were in their early twenties when they launched what would become world-changing companies. Do these famous cases reflect a generalizable pattern? VC and media accounts seem to suggest so.

IPO 13

The Limits of 3D Printing

Harvard Business Review

Exciting applications have already been demonstrated across all sectors — from aerospace and medical applications to biotechnology and food production.

The Promise and Challenge of Big Data for Pharma

Harvard Business Review

From our unique vantage points at Genentech , a leading biotechnology company with a major data science practice, and The Data Incubator , a data-science education company that places and trains data scientists , we have seen how the pharmaceuticals industry has leveraged big data for some potentially revolutionary advances and the challenges it has faced along the way.

The Reason Silicon Valley Beat Out Boston for VC Dominance

Harvard Business Review

In contrast, New England has increasingly become a hub for ventures in life sciences; the first three-quarters of 2016 saw almost 60% of VC investments in New England go to ventures in biotechnology and medical devices. Despite the East Coast roots of technology entrepreneurship and venture capital (VC), by the 1990s Silicon Valley had gained a major advantage over the Cambridge-Boston area. In 1995 Silicon Valley’s share of all VC investments in the U.S.

Innovation Should Be a Top Priority for Boards. So Why Isn’t It?

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Jason Jaroslav Cook Creative/Getty Images.

Think Global, Not Emerging Markets, Century

Harvard Business Review

Another CEO of a fast-growing biotechnology venture, a Chinese-American entrepreneur, added that he wanted his company to be perceived as American rather than as Chinese. Nokia's recent burning platform travails serve as an object lesson to companies trying to navigate a rapidly-changing global economy. As multinational corporations pursue opportunities in emerging markets, they're bound to stumble if they overlook the developed economies, and vice versa.

7 Charts Show How Political Affiliation Shapes U.S. Boards

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Are corporate boards as polarized politically as the general population?

New Research: Where the Talent Wars Are Hottest

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Why Women Feel More Stress at Work

Harvard Business Review

In one study, female and male MBA students were paired and asked to negotiate the purported purchase of a biotechnology plant. Everyone in today’s supercharged workplaces experiences stress.

So Many M&A Deals Fail Because Companies Overlook This Simple Strategy

Harvard Business Review

The rationale for this approach is highlighted when you compare, for example, the different approaches to M&A employed by a number of legacy pharmaceutical companies and by some relatively newer players in the biotechnology industry.

Give Impact Investing Time and Space to Develop

Harvard Business Review

In impact investing, we need to find a way to place that same premium on social impact by valuing the public good being created – just like we do in early stage R&D in science, IT, health, and biotechnology. Impact investing has captured the world’s imagination.

What You Might Not Know About the Cuban Economy

Harvard Business Review

It could be an ideal location for healthcare organizations, but also for those in applied sciences, biotechnology, and pharmaceuticals. And secondly, the business model for Cuban biotechnology has been laughably bad.

The Political Issues Board Directors Care Most About

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., With the 2016 U.S. presidential election season upon us, what political issues most concern business leaders?

Talent Management: Boards Give Their Companies an "F"

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., What is top of mind for corporate boards worldwide?

Why It’s So Hard to Train Someone to Make an Ethical Decision

Harvard Business Review

Take the decision of Sam Waksal, the former CEO of the emerging biotechnology company ImClone Systems. One of the conundrums of ethical decision making is that many moral decisions that are quite straightforward — even easy — to resolve in a classroom or during training exercises seem far more difficult to successfully resolve when confronted during actual day-to-day decision making.

Joining Boards: It's Not Just Who You Know That Matters

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., For many, a corporate directorship is a career capstone. But attaining one is far from easy.

Who's Really Responsible for P&G's Succession Problems?

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., People will continue to debate Procter & Gamble''s move to replace CEO Bob McDonald with his immediate predecessor A.G.

Taxpayers Helped Apple, but Apple Won't Help Them

Harvard Business Review

It is not by accident that the National Institutes of Health spends $31 billion a year on supporting innovation in biotechnology and pharmacology. Over the years. taxpayers have been very good to Apple.

How to Get Yourself Invited to Important Meetings

Harvard Business Review

She was on the legal compliance team at a fast-growing biotechnology company. MINCHU/Getty Images. In a work culture with too many meetings, we often look for tactics to get out of meetings. But sometimes you need to get into a meeting, perhaps because the decisions made there will have implications for you or your team, or maybe because you feel you’ve been left out of important discussions.

When Will this Low-Innovation Internet Era End?

Harvard Business Review

There are intriguing signs that we might be approaching the point where digital innovation takes a big leap into the physical world: 3D printers are breaking into the mainstream , tech billionaires are backing an asteroid mining venture , and lots of people keep saying that biotechnology is the next great frontier. It's an age of unprecedented, staggering technological change. Business models are being transformed, lives are being upended, vast new horizons of possibility opened up.

How We Built a New Company Culture

Harvard Business Review

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. Too often, any thought of changing a culture, never mind rebuilding it, seems like a Sisyphean task; the weight of the status quo ultimately rolls back and crushes such efforts. To save the 20-year-old company, I had to get it operating like a start-up.

Don’t Judge the Economy by the Number of Start-Ups

Harvard Business Review

More new businesses are better for society, right? That’s a common assumption. For instance, take this recent Washington Post piece , headlined, “More businesses are closing than starting. Can Congress help turn that around?” Sounds ominous at first. But wait a minute – is starting more new businesses always a good thing?

Developing Global Leaders Is America's Competitive Advantage

Harvard Business Review

French pharmaceutical company Sanofi recently acquired Boston-based Genzyme to tap into America's intellectual capital in biotechnology. As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. American companies and academic institutions possess unique competitive advantages in developing these global leaders.

Why Boards Aren’t Dealing with Cyberthreats

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., One of the greatest challenges facing boards today is the one directors feel least prepared for: cybersecurity. Yahoo’s disclosure in December of what could be the largest data breach in history was hardly an isolated incident. Indeed, the Guardian dubbed 2016 the “year of the hack,” and cyberthreats are increasingly common across all sectors.

Should Big Companies Give Up on Innovation?

Harvard Business Review

Start-up companies tend to cluster in industries favored by venture capitalists (like biotechnology or information technology) or ones where there are relatively low barriers to entry (like restaurants). “Why bother?”. It’s a common question thrown at me by entrepreneurs, venture capitalists, or the more cynically minded corporate leaders.

Five Questions Companies Should Ask Before Making an Innovation-Driven Acquisition

Harvard Business Review

In pharma, Johnson & Johnson's 1999 acquisition of Centocor brought in blockbuster biotechnology innovations led by rheumatoid arthritis drug Remicade. The Swiss pharmaceutical giant Roche is nothing if not determined in its quest to acquire Illumina, the San Diego-based leader in genetic-sequencing equipment. In January, after Illumina's board rebuffed Roche's initial overtures, Roche made a $5.7 billion tender offer directly to shareholders.